A controlled trial of maprotiline (Ludiomil) in depressed outpatients.
A double blind comparison is reported of a new tetracyclic antidepressant, maprotiline, with amitriptyline and placebo in psychiatric outpatients. Amitriptyline was significantly more effective than placebo in its global effect on depression. Maprotiline emerged as neither inferior to amitriptyline nor superior to placebo. Methodological difficulties prevented an adequate assessment of the anxiolytic activity of maprotiline.
D000328:Adult; D000639:Amitriptyline / Q000009:adverse effects / Q000627:therapeutic use; D000873:Anthracenes / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000009:adverse effects / Q000627:therapeutic use*; D010044:Outpatient Clinics, Hospital; D010919:Placebos; D011569:Psychiatric Status Rating Scales
D000873:Anthracenes; D010919:Placebos; D000639:Amitriptyline; D008376:Maprotiline